Translational Development Acquisition Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 16, 2026, reporting a net loss of $9,293,622 for the third quarter and disclosing a new $10,200,000 Subscription Agreement liability on its balance sheet.

Key Highlights

  • Net loss of $9,293,622 for the three months ended September 30, 2026, compared to net income of $1,660,122 in the same period of 2025, according to the filing.
  • Loss on issuance of Subscription Agreement of $11,000,000 recorded in Q3 2026, partially offset by a $800,000 change in fair value of the Subscription Agreement liability, the company disclosed.
  • Marketable securities held in Trust Account stood at $159,316,656 as of September 30, 2026, down from $181,657,311 at December 31, 2025.
  • 14,651,303 Class A ordinary shares subject to possible redemption at a redemption value of $10.87 per share as of September 30, 2026, the filing stated.
  • 4,657,499 Class B ordinary shares converted to Class A during Q2 2026, leaving only 1 Class B ordinary share outstanding as of November 16, 2026, per the filing.
  • Total shareholders' deficit widened to $(19,032,730) at September 30, 2026, from $(6,542,108) at December 31, 2025, the registrant reported.
  • Promissory note payable to a related party increased to $2,150,000 as of September 30, 2026, from $200,000 at December 31, 2025, according to the filing.

Subscription Agreement Loss and Trust Account Drawdown Drive Q3 2026 Results

Translational Development Acquisition Corp. (NASDAQ:TDAC), a Cayman Islands-incorporated blank check company based in New York, reported a net loss of $9,293,622 for the three months ended September 30, 2026, according to its Form 10-Q filed November 16, 2026. The primary driver was a $11,000,000 loss on the issuance of a Subscription Agreement, which the company also recorded as a $10,200,000 Subscription Agreement liability on its balance sheet. A $800,000 favorable change in the fair value of that liability partially offset the charge, the filing disclosed.

General and administrative costs for the three months ended September 30, 2026 were $548,411, up from $213,658 in the comparable prior-year period. For the nine months ended September 30, 2026, general and administrative costs totaled $1,490,622, compared to $782,193 for the same period in 2025. Dividends earned on marketable securities held in the Trust Account were $1,454,789 for Q3 2026 and $4,676,779 for the nine-month period, the registrant reported.

The balance sheet as of September 30, 2026 showed total assets of $159,406,410, with $159,316,656 held in the Trust Account. Total liabilities reached $19,122,484, including the new $10,200,000 Subscription Agreement liability and a $6,037,500 deferred underwriting fee that remained unchanged from December 31, 2025. Cash on hand was $85,852. The accumulated deficit grew to $(19,033,196) from $(6,542,574) at December 31, 2025. During Q2 2026, 4,657,499 Class B ordinary shares were converted to Class A ordinary shares, leaving 1 Class B ordinary share outstanding as of the filing date, the company disclosed.

What Was Disclosed

The filing covers Translational Development Acquisition Corp.'s unaudited financial results for the three and nine months ended September 30, 2026, including a new Subscription Agreement liability, a reduced Trust Account balance following redemptions, and a sharply widened shareholders' deficit.